The effects of the nonsteroidal anti-inflammatory drug diclofenac sodium on the rat kidney, and alteration by furosemide

2008 ◽  
Vol 41 (4) ◽  
pp. 919-926 ◽  
Author(s):  
Ayberk Besen ◽  
Fatih Kose ◽  
Saime Paydas ◽  
Gulfiliz Gonlusen ◽  
Tamer Inal ◽  
...  
2004 ◽  
Vol 37 (9) ◽  
pp. 1582-1587 ◽  
Author(s):  
Koichiro Sato ◽  
Junji Sagawa ◽  
Ryo Ichinohasama ◽  
Hiroyuki Kumamoto ◽  
Masato Yamaguchi

2007 ◽  
Vol 30 (3) ◽  
pp. 242-249 ◽  
Author(s):  
Noton Kumar Dutta ◽  
Subramanian Annadurai ◽  
Kaushiki Mazumdar ◽  
Sujata G. Dastidar ◽  
Jette E. Kristiansen ◽  
...  

2007 ◽  
Vol 45 (3) ◽  
pp. 443-449 ◽  
Author(s):  
Monica Bartolomei ◽  
Andrea Rodomonte ◽  
Eleonora Antoniella ◽  
Giuliano Minelli ◽  
Paola Bertocchi

2018 ◽  
Vol 34 (1) ◽  
pp. 67-72 ◽  
Author(s):  
Kubra Koc ◽  
Salim Cerig ◽  
Nihal Simsek Ozek ◽  
Ferhunde Aysin ◽  
Serkan Yildirim ◽  
...  

2010 ◽  
Vol 55 (2) ◽  
pp. 139-144 ◽  
Author(s):  
Bhulan Kumar Singh ◽  
Rahila Ahmad Pathan ◽  
Krishna Kolappa Pillai ◽  
Syed Ehtaishamul Haque ◽  
Kiran Dubey

1998 ◽  
Vol 95 (5) ◽  
pp. 603-609 ◽  
Author(s):  
Marijke HAAS ◽  
Frits MOOLENAAR ◽  
Dirk K. F. MEIJER ◽  
Paul E. DE JONG ◽  
Dick DE ZEEUW

1.Renal specific targeting of the non-steroidal anti-inflammatory drug naproxen was obtained by coupling to the low-molecular-mass protein lysozyme. A previous study showed that conjugation to lysozyme resulted in a 70-fold increase of naproxen accumulation in the kidney with a subsequent renal release of the active metabolite naproxen–lysine. 2.In the present study we questioned whether naproxen–lysozyme is active in the rat kidney, inhibiting the urinary excretion of prostaglandin E2 and renal sodium and water excretion in salt-restricted baseline conditions as well as during frusemide treatment. 3.A high dose of free naproxen (10 ;mg·day-1·kg-1) did not affect prostaglandin E2 excretion in baseline conditions (naproxen, 11±1 ;ng/8 ;h; vehicle, 13±4 ;ng/8 ;h), whereas sodium and water excretion were, respectively, 3.0 and 1.6 times lower in the naproxen group (P< 0.05). Naproxen completely prevented the frusemide-induced increase (3-fold) in prostaglandin E2 excretion (naproxen 6.6±1.1 ;ng/8 ;h, vehicle 40±12 ;ng/8 ;h, P< 0.005). Frusemide-stimulated natriuresis and diuresis were, respectively, 1.6 (P< 0.05) and 1.8 times (P< 0.005) lower in the naproxen group. 4.A dose of 2 ;mg·day-1·kg-1 lysozyme-conjugated naproxen did not affect prostaglandin E2 excretion in baseline conditions (conjugate, 18±2 ;ng/8 ;h; vehicle, 24±5 ;ng/8 ;h). The conjugate also had no effect on sodium and water excretion. However, the naproxen conjugate completely prevented the frusemide-induced increase (2-fold) in prostaglandin E2 excretion (conjugate, 16±3 ;ng/8 ;h; vehicle, 48±13 ;ng/8 ;h, P< 0.05). Surprisingly, frusemide-induced natriuresis and diuresis were not affected by the conjugate. 5.In conclusion, a renal specific delivery of the non-steroidal anti-inflammatory drug naproxen using lysozyme results in an inhibitory effect on renal prostaglandin E2 synthesis but does not affect the excretion of sodium and water, in contrast to free naproxen.


Sign in / Sign up

Export Citation Format

Share Document